Atrial fibrillation: will new drugs and patient choice improve anticoagulation outcomes?

R Fuller, N J Dudley

The growing epidemic of atrial fibrillation presents major challenges to the healthcare community, both clinical and financial.

The management of non-valvar atrial fibrillation (AF) presents a significant challenge to clinicians worldwide, with an estimated 2.5 million patients affected across the USA and UK alone. At least 15% of all ischaemic strokes may be attributable to underlying AF and an individual’s annual risk of stroke may be as high as 18% depending on the number of risk factors, including age. With the number of stroke events expected to rise as the prevalence of AF and the aging population increases, this “epidemic” of AF has significant financial implications; a recent economic analysis suggested that almost 1% of National Health Service expenditure in 2000 arose because of AF and its related outcomes. Improving prevention of AF related strokes should be a healthcare priority from both an individual and a national point of view.

ANTICOAGULANTS: RISKS, CONTROL, AND OUTCOMES

Large scale trials have demonstrated the efficacy of both aspirin and warfarin in preventing thromboembolic stroke associated with AF, with a respective 22% and 62% relative risk reduction in rates of stroke. Why then do so few patients receive warfarin despite its clear benefits? There is clear evidence that significant numbers of patients do not receive anticoagulation when it is appropriate and community surveys suggest that less than 25% of those who are eligible receive warfarin treatment. Decisions around anticoagulation are complex and heuristical with physicians striving to balance risks and benefits, often avoiding adverse bleeding related outcomes, but overlooking the unexplained benefits of stroke prevention. For both physicians and patients, the annual risk of intracerebral bleeding of up to 2% is a major contributing factor in a decision to withhold or avoid warfarin. For those patients who do opt for warfarin, long-term anticoagulation poses many problems—regular phlebotomy based monitoring, drug and food interactions, the effects of intercurrent illness and dose variability. The report in this issue of Heart by Jones and colleagues examines the relation of warfarin control and outcomes in more detail, revealing that patients in their study spent approximately 30% of the time outside target international normalised ratio (INR) values. Although a registry based study, and as such unable to control for confounding factors such as illness or medication changes, suboptimal control was clearly linked with an increased risk of ischaemic stroke or bleeding.

Near patient testing (NPT) with computerised support can improve on this level of poor control, with one study showing only 14% of patients outside of target INR range. Studies of self managed patients have recorded just 26% of results outside of target range. Although such studies have involved smaller numbers of patients compared to Jones’s study, they do demonstrate an alternative mode of service delivery involving primary care that has the added benefit of improved patient satisfaction.

In the current financial climate, there would need to be significant incentives for general practitioners to develop and deliver such a warfarin based anticoagulation service.

ORAL DIRECT THROMBIN INHIBITORS

Does the new oral direct thrombin inhibitor ximelagatran represent a suitable alternative to warfarin for the individual patient? Data from the SPORTIF III and V studies shows promising results in stroke risk reduction in AF, with comparable effects to warfarin in direct trials in prevention of stroke and systemic embolic events. Ximelagatran presents an attractive proposition with no significant food or drug interactions, fixed dosing, and no need to monitor its anticoagulant effects as the target of appropriate anticoagulation is taken as read. There is, however, still a need for blood tests and monitoring as 6% of patients developed abnormal liver function tests in the SPORTIF trials. Ximelagatran compared favourably with warfarin in terms of major non-stroke related haemorrhage risk (1.3%/annum with ximelagatran vs 1.8%/annum with warfarin) in the SPORTIF III trial and has been heralded by some as the anticoagulant of choice for older people with AF. However, this may prove to be an optimistic prediction as parity in bleeding events was based on patients taking ximelagatran at an appropriate, non-monitored level of anticoagulation compared with 44% of warfarin subjects out of range (INR > 3.0). The advent of NPT schemes and tighter warfarin control may negate much of the considered benefit of ximelagatran if effective NPT control can reduce bleeding rates with warfarin.

Abbreviations: AF, atrial fibrillation; INR, international normalised ratio; NPT, near patient testing
Although rates of minor bleeding were less with ximelagatran, the parity in major bleeding episodes suggests that uptake of ximelagatran is unlikely to be significantly greater than existing rates of warfarin prescribing as physicians and individual patients are still faced with comparable rates of potentially lethal bleeding, a factor shown to be key in decisions whether to choose anticoagulation.17 18 For older patients, a group often excluded from anticoagulant therapy, this comparable risk of major bleeding may not alter current practices of avoiding anticoagulation because of concerns regarding adverse events.19

INDIVIDUALISING PATIENT RISK AND DECISION MAKING IN AF

Given the individual and economic burden of AF related stroke disease, how can anticoagulant prescribing be improved? While systematised approaches to prescribing may raise awareness of the need for anticoagulation, this strategy alone is unlikely to be successful in increasing numbers of eligible patients receiving anticoagulation unless supported by a more individualised approach to treatment choice. The use of a more detailed and individualised stroke risk estimate based on risk factors and an estimate of intracerebral bleeding risk may help an individual reach a more informed decision about whether or not to choose warfarin.4 6

However, there are some emerging concerns. Data about the increased risks of anticoagulation in patients with cerebral small vessel disease is likely to complicate further any risk versus benefit calculation. For many patients with AF and increased risk of embolic stroke, their concurrent vascular co-morbidities—namely hypertension, diabetes mellitus, and older age—are also risks for small vessel disease and the associated increased rates of intracerebral bleeding when anticoagulated or given antiplatelet agents.7 8 The routine use of magnetic resonance imaging in AF patients to rule out the presence of microbleeds that can mark out an individual at an increased risk of intracerebral bleeding may be one way of improving patient choice and use of an anticoagulant agent.

Much of this may seem rather theoretical and rather impractical to the busy clinician. However, it is important as just as clinicians have a responsibility to obtain informed consent for interventional procedures, the potential risks associated with the use of warfarin or an alternative agent means that physicians too have a legal responsibility to inform patients of significant risks so that a patient has the information available to determine what treatment should be accepted or rejected.19

Achieving successful management of AF and stroke risk reduction is unlikely to be achieved solely through wholesale adoption of new direct thrombin inhibitors over warfarin, but through careful selection of patients and discussion of individualised risk and benefit information. Using decision and risk models to examine the relative merits of treatment, developing NPT and computerised dosing support if newer agents prove too expensive, and most importantly understanding the individual patient’s choices for treatment should be key targets for all clinicians to combat the growing AF epidemic and improve the wider and appropriate use of anticoagulants.

REFERENCES

Atrial fibrillation: will new drugs and patient choice improve anticoagulation outcomes?

R Fuller and N J Dudley

*Heart* 2005 91: 423-424
doi: 10.1136/hrt.2004.047902

Updated information and services can be found at:
http://heart.bmj.com/content/91/4/423

These include:

**References**
This article cites 18 articles, 10 of which you can access for free at:
http://heart.bmj.com/content/91/4/423#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

Drugs: cardiovascular system (8842)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/